0001193125-21-331409.txt : 20211117 0001193125-21-331409.hdr.sgml : 20211117 20211116174211 ACCESSION NUMBER: 0001193125-21-331409 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20211115 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20211117 DATE AS OF CHANGE: 20211116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IN8BIO, INC. CENTRAL INDEX KEY: 0001740279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 825462585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39692 FILM NUMBER: 211417568 BUSINESS ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (646) 600-6438 MAIL ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Incysus Therapeutics, Inc. DATE OF NAME CHANGE: 20180510 8-K 1 d238625d8k.htm 8-K 8-K
false 0001740279 0001740279 2021-11-15 2021-11-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 15, 2021

 

 

IN8bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39692   82-5462585

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

350 5th Avenue, Suite 5330

New York, New York

   10118
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 646 600-6438

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value   INAB   NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of November 15, 2021, IN8bio, Inc. (the “Company”) appointed Dr. Trishna Goswami as the Company’s Chief Medical Officer.

In connection with her appointment as Chief Medical Officer, the Company entered into an employment agreement with Dr. Goswami (the “Employment Agreement”), pursuant to which Dr. Goswami will be employed by the Company on an at-will basis. She will be paid an annual base salary of $450,000 and will be eligible for an annual bonus targeted at 40% of her base salary. The Company also awarded Dr. Goswami a signing bonus of $10,000, provided that, in the event Dr. Goswami resigns from the Company without Good Reason (as defined in the Employment Agreement) at any time prior to the one-year anniversary of her start date, Dr. Goswami must repay the signing bonus. Dr. Goswami will be awarded an option to purchase 250,000 shares of the Company’s common stock, vesting over four years, with 25% vesting after the first anniversary of the grant date, subject to her continued employment with the Company. Dr. Goswami will be eligible to receive certain severance benefits in connection with a termination of her employment by the Company without Cause (as defined in the Employment Agreement) or by Dr. Goswami for Good Reason, in each case, subject to execution of a release and settlement agreement. If such termination occurs, Dr. Goswami shall be entitled to receive 12 months of her then current base salary, including the pro rata portion of her target bonus (assuming completion of performance goals) and her COBRA premiums for nine months.

Dr. Goswami most recently served as Vice President Clinical Development at Gilead Sciences, Inc. (via its $21 billion acquisition of Immunomedics in 2020), where she led a team that secured accelerated approval of Trodelvy® in bladder cancer and was a key contributor to securing full FDA approval in triple-negative breast cancer. Prior to Gilead/Immunomedics, she served as a Senior Medical Director at Stemline Therapeutics, Inc., where she oversaw the development of multiple hematologic assets and helped secure approval of ELZONRIS® (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm, a rare leukemia. Dr. Goswami was previously at MedImmune, then AstraZeneca/MedImmune post-acquisition, where she managed biologics development for hematologic indications, launching the first phase 3 trial in an oncology indication at MedImmune. At AstraZeneca, Dr. Goswami also participated in the development of IMFINZI® (durvalumab) and tremelimumab. Before her career in industry, Dr. Goswami served as Assistant Professor, Department of Medicine, Division of Hematology/Oncology at the University of Maryland. She is an author of multiple publications during her tenure in academia and industry. Dr. Goswami earned her M.D. from Drexel University College of Medicine, completed her postgraduate training in internal medicine and hematology/oncology at Georgetown University Hospital and completed her MBA from the Smith School of Business at the University of Maryland.

The foregoing summary of the Employment Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which will be filed as an exhibit to the Company’s Form 10-K for the year ending December 31, 2021, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    IN8bio, Inc.
Date:    November 16, 2021     By:  

/s/ Patrick McCall

      Patrick McCall
      Chief Financial Officer and Secretary
 EX-101.SCH 2 inab-20211115.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 inab-20211115_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 inab-20211115_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d238625d8k_htm.xml IDEA: XBRL DOCUMENT 0001740279 2021-11-15 2021-11-15 false 0001740279 8-K 2021-11-15 IN8bio, Inc. DE 001-39692 82-5462585 350 5th Avenue Suite 5330 New York NY 10118 646 600-6438 false false false false Common Stock, $0.0001 par value INAB NASDAQ true false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 15, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001740279
Document Type 8-K
Document Period End Date Nov. 15, 2021
Entity Registrant Name IN8bio, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39692
Entity Tax Identification Number 82-5462585
Entity Address, Address Line One 350 5th Avenue
Entity Address, Address Line Two Suite 5330
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10118
City Area Code 646
Local Phone Number 600-6438
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value
Trading Symbol INAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d238625d8k.htm inab-20211115.xsd inab-20211115_lab.xml inab-20211115_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d238625d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d238625d8k.htm" ] }, "labelLink": { "local": [ "inab-20211115_lab.xml" ] }, "presentationLink": { "local": [ "inab-20211115_pre.xml" ] }, "schema": { "local": [ "inab-20211115.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "inab", "nsuri": "http://in8bio.com/20211115", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d238625d8k.htm", "contextRef": "duration_2021-11-15_to_2021-11-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d238625d8k.htm", "contextRef": "duration_2021-11-15_to_2021-11-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://in8bio.com//20211115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-21-331409-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-331409-xbrl.zip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end